Economic evaluation of strategies against coronavirus : a systematic review

Background The COVID-19 outbreak was defned as a pandemic on 11 March 2020 by the World Health Organization. After that, COVID-19 has enormously infuenced health systems around the world, and it has claimed more than 4.2 million deaths until July 2021. The pandemic has led to global health, social and economic costs. This situation has prompted a crucial search for benefcial interventions and treatments, but little is known about their monetary value. This study is aimed at systematically reviewing the articles conducted on the economic evaluation of preventive, control and treatment strategies against COVID-19. Material and method We searched PubMed, Web of Science, Scopus, and Google Scholar from December 2019 to October 2021 to fnd applicable literature to the economic evaluation of strategies against COVID-19. Two researchers screened potentially eligible titles and abstracts. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist was used to quality assessment of studies. Results Thirty-six studies were included in this review, and the average CHEERS score was 72. Cost-efectiveness analysis was the most common type of economic evaluation, used in 21 studies. And the quality-adjusted life year (QALY) was the main outcome applied to measure the efectiveness of interventions, which was used in 19 studies. In addition, articles were reported a wide range of incremental cost-efectiveness ratio (ICER), and the lowest cost per QALY ($321.14) was related to the use of vaccines. Conclusion Based on the results of this systematic review, it seems that all strategies are likely to be more costefective against COVID-19 than no intervention and vaccination was the most cost-efective strategy. This research provides insight for decision makers in choosing optimal interventions against the next waves of the current pandemic and possible future pandemics.